Literature DB >> 16737918

Inversions of chromosomes 2 and 6 in mantle cell lymphoma. Cytogenetic, FISH, and molecular studies.

Estela Pedrazzini1, Roxana Cerretini, María Fernanda Noriega, Marina Narbaitz, María Fernanda Palacios, Pedro Negri, Raquel Bengió, Irma Slavutsky.   

Abstract

Inversions are infrequent events in hematological malignancies. We here report the cytogenetic, fluorescence in situ hybridization (FISH), and molecular studies of 2 patients diagnosed with mantle cell lymphoma (MCL) that showed inversions of chromosomes 2 and 6 as part of complex karyotypes. Both patients showed a cytogenetically identical inv(6)(p23q11) detected as a secondary aberration. In addition, both patients had a derivative chromosome 2 which originated by partial deletion of the short arm and a pericentric inversion with different breakpoints on the long arm: der(2)del(2)(p21)inv(2)(p21q11) and der(2)del(2)(p21)inv(2)(p21q13), respectively. The presence of t(11;14)(q13;q32) was confirmed by interphase FISH and by molecular study. Residual normal cells were found in both cases. The patients showed a different clinical evolution with a poor outcome for one case and a favorable course of the disease for the other one. The review of the literature in MCL showed a total of 9 inversions affecting different chromosomes. Considering that inversions are very infrequent events in MCL, our findings could be important for detecting genes potentially involved in development and/or progression of this aggressive non-Hodgkin lymphoma subtype.

Entities:  

Mesh:

Year:  2006        PMID: 16737918     DOI: 10.1016/j.cancergencyto.2005.12.004

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  1 in total

1.  Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma.

Authors:  Amanda Gonçalves Dos Santos Silva; Herbert Alexander Graves; Amanda Guffei; Tatiana Iervolino Ricca; Renato Arruda Mortara; Miriam Galvonas Jasiulionis; Sabine Mai
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.